Houng Kim
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Journal: Drugs
Published: February 01, 2020
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
Journal: Cancer chemotherapy and pharmacology
Published: June 22, 2018
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Journal: Lancet (London, England)
Published: May 17, 2018
Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Journal: Future oncology (London, England)
Published: February 28, 2018
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Journal: Annals of the rheumatic diseases
Published: October 17, 2015
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Journal: Annals of the rheumatic diseases
Published: October 16, 2015
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Journal: Expert review of gastroenterology & hepatology
Published: September 24, 2015
Biosimilars for the management of rheumatoid arthritis: economic considerations.
Journal: Expert review of clinical immunology
Published: September 24, 2015
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Journal: Annals of the rheumatic diseases
Published: May 21, 2013
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Journal: Annals of the rheumatic diseases
Published: May 21, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026